Trial Profile

A Phase Ib/II, Open-Label Study of M7824 in Combination With Chemotherapy in Participants With Stage IV Non-small Cell Lung Cancer

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 14 Sep 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bintrafusp alfa (Primary) ; Carboplatin (Primary) ; Cisplatin (Primary) ; Docetaxel (Primary) ; Gemcitabine (Primary) ; Paclitaxel (Primary) ; Pemetrexed (Primary)
Indications Non-small cell lung cancer
Focus Adverse reactions
Acronyms INTR@PID LUNG 024
Sponsors EMD Serono Research & Development Institute; Merck KGaA

26 Sep 2022 Results deriving PK and AE data from studies NCT02517398, NCT02699515, NCT03840915, and NCT04246489; describing a model-informed dose modification approach for risk management of Bintrafusp alfa associated bleeding adverse events, published in the Cancer Chemotherapy and Pharmacology
10 Aug 2022 Status changed from active, no longer recruiting to completed.
01 Feb 2022 Planned End Date changed from 28 Jan 2022 to 29 Jul 2022.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com